Last reviewed · How we verify

Glimepiride 2 mg

Merck Sharp & Dohme LLC · FDA-approved active Small molecule Quality 5/100

Glimepiride 2 mg is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved. Also known as: Solosa, Amaryl.

Glimepiride 2 mg, marketed by Merck Sharp & Dohme LLC, is an established product in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and long-term use. The primary risk is the potential increase in generic competition following the patent expiry in 2028.

At a glance

Generic nameGlimepiride 2 mg
Also known asSolosa, Amaryl
SponsorMerck Sharp & Dohme LLC
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Glimepiride 2 mg

What is Glimepiride 2 mg?

Glimepiride 2 mg is a Small molecule drug developed by Merck Sharp & Dohme LLC.

Who makes Glimepiride 2 mg?

Glimepiride 2 mg is developed and marketed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

Is Glimepiride 2 mg also known as anything else?

Glimepiride 2 mg is also known as Solosa, Amaryl.

What development phase is Glimepiride 2 mg in?

Glimepiride 2 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing